A detailed history of Tower Research Capital LLC (Trc) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 87 shares of KRYS stock, worth $14,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87
Previous 2,202 96.05%
Holding current value
$14,340
Previous $404,000 96.29%
% of portfolio
0.0%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$174.7 - $213.66 $369,490 - $451,890
-2,115 Reduced 96.05%
87 $15,000
Q2 2024

Aug 13, 2024

BUY
$153.12 - $183.64 $86,512 - $103,756
565 Added 34.51%
2,202 $404,000
Q1 2024

May 15, 2024

BUY
$108.01 - $179.35 $41,151 - $68,332
381 Added 30.33%
1,637 $291,000
Q4 2023

Feb 13, 2024

SELL
$96.0 - $128.29 $33,600 - $44,901
-350 Reduced 21.79%
1,256 $155,000
Q3 2023

Nov 14, 2023

BUY
$108.51 - $130.22 $98,852 - $118,630
911 Added 131.08%
1,606 $186,000
Q2 2023

Aug 14, 2023

SELL
$78.48 - $130.32 $20,483 - $34,013
-261 Reduced 27.3%
695 $81,000
Q1 2023

May 09, 2023

BUY
$72.39 - $84.27 $41,334 - $48,118
571 Added 148.31%
956 $77,000
Q4 2022

Feb 10, 2023

SELL
$63.14 - $79.9 $195,228 - $247,050
-3,092 Reduced 88.93%
385 $31,000
Q3 2022

Nov 10, 2022

BUY
$64.85 - $82.4 $46,043 - $58,504
710 Added 25.66%
3,477 $242,000
Q2 2022

Aug 15, 2022

SELL
$48.93 - $73.47 $17,565 - $26,375
-359 Reduced 11.48%
2,767 $181,000
Q1 2022

May 12, 2022

SELL
$51.99 - $72.11 $128,571 - $178,328
-2,473 Reduced 44.17%
3,126 $208,000
Q4 2021

Feb 14, 2022

BUY
$39.81 - $88.24 $126,954 - $281,397
3,189 Added 132.32%
5,599 $391,000
Q3 2021

Nov 15, 2021

BUY
$52.01 - $71.77 $29,021 - $40,047
558 Added 30.13%
2,410 $126,000
Q2 2021

Aug 16, 2021

BUY
$62.14 - $81.82 $45,610 - $60,055
734 Added 65.65%
1,852 $126,000
Q1 2021

May 17, 2021

BUY
$59.42 - $85.46 $28,165 - $40,508
474 Added 73.6%
1,118 $87,000
Q4 2020

Feb 16, 2021

BUY
$40.64 - $61.38 $13,045 - $19,702
321 Added 99.38%
644 $39,000
Q3 2020

Nov 16, 2020

SELL
$37.76 - $48.49 $126,458 - $162,393
-3,349 Reduced 91.2%
323 $14,000
Q2 2020

Aug 13, 2020

BUY
$37.03 - $60.0 $135,974 - $220,320
3,672 New
3,672 $152,000
Q1 2020

May 15, 2020

SELL
$35.02 - $65.64 $41,323 - $77,455
-1,180 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$33.17 - $65.23 $16,485 - $32,419
497 Added 72.77%
1,180 $65,000
Q3 2019

Nov 05, 2019

SELL
$34.72 - $51.3 $38,608 - $57,045
-1,112 Reduced 61.95%
683 $23,000
Q2 2019

Aug 13, 2019

BUY
$27.2 - $41.2 $48,824 - $73,954
1,795 New
1,795 $72,000
Q1 2019

May 14, 2019

SELL
$19.86 - $32.9 $22,640 - $37,506
-1,140 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$15.03 - $25.38 $22,349 - $37,740
-1,487 Reduced 56.6%
1,140 $24,000
Q3 2018

Nov 13, 2018

BUY
$14.43 - $21.0 $37,907 - $55,167
2,627 New
2,627 $46,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.23B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.